AUTL
What one share of Autolus Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune diseases. Using our broad suite of proprietary and modular T cell programming technologies, we are engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate target cells.
Autolus Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.44 |
|---|---|
| Profit | −$1.05 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$0.87 |
| Cash and investments | $0.64 |
| Book value | $0.28 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.12 | −$1.26 | $0.19 | −$1.18 | — | $3.09 |
| 2017 | $0.12 | −$1.43 | $0.21 | −$1.40 | — | $10.35 |
| 2018 | $0.04 | −$1.42 | $0.29 | −$1.29 | — | $6.36 |
| 2019 | $0.07 | −$2.88 | $0.43 | −$2.78 | — | $5.67 |
| 2020 | — | −$2.76 | $0.28 | −$2.57 | — | $4.01 |
| 2021 | — | −$1.97 | $0.12 | −$1.76 | — | $3.45 |
| 2022 | — | −$1.57 | $0.11 | −$1.30 | — | $1.73 |
| 2023 | $0.01 | −$1.20 | $0.06 | −$0.90 | — | $0.42 |
| 2024 | $0.04 | −$0.86 | $0.09 | −$0.89 | — | $1.61 |
| 2025 | $0.28 | −$1.08 | $0.07 | −$1.14 | — | $0.67 |